Abbott Laboratories (ABT) stock slipped on Wednesday after the healthcare company reported its Q1 2025 earnings. Its adjusted earnings per share for the quarter came in at $1.09, just above Wall Street’s estimate of $1.07. That’s also a 9.2% improvement over the 98 cents per share reported in the same period of the year prior.
Abbott Laboratories reported revenue of $10.36 billion in its Q1 2025 earnings report. That’s a miss compared to the analysts revenue estimate of $10.41 billion for the quarter. This is despite the company’s revenue growing 4% year-over-year from $9.96 billion.
The mixed Q1 earnings report didn’t sit well with ABT stockholders. That sent shares down 0.37% in pre-market trading today. It also followed a 0.9% drop on Tuesday ahead of the report. Even so, ABT stock remains up 12.7% year-to-date.
Abbott Laboratories Guidance
Abbott Laboratories reaffirmed its 2025 guidance in its latest earnings report. It expects adjusted EPS to range from $1.23 to $1.27 in Q2, compared to Wall Street’s $1.25 estimate. For the full year of 2025, ABT predicts adjusted EPS of $5.05 to $5.25, compared to the analyst estimate of $5.15.
Abbott Laboratories also reaffirmed its organic sales growth outlook of 7.5% to 8.5% for 2025, as well as its adjusted operating margin guidance of 23.5% to 24% of sales.
Abbott Laboratories did not provide revenue guidance in its Q1 earnings report. Even so, analyst expectations are known. According to Main Street Data, analysts’ revenue estimates are $11.2 billion for Q2, $11.4 billion for Q3, and $11.8 billion for Q4.
Is ABT Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Abbott Laboratories is Strong Buy, based on 14 Buy and two Hold ratings over the last three months. With that comes an average price target of $140.57, representing a potential 11.37% upside for ABT stock. These ratings and price targets will likely change as analysts update their coverage after today’s earnings.
